Recently, empagliflozin and canagliflozin, which are sodium-glucose cotransporter 2 (SGLT2) inhibitors, were reported to reduce all-cause mortality, cardiovascular mortality, and hospitalization due to heart failure in T2DM [16–19]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.